연구업적

연도	2024년	2023년	2022년	2021년	2020년
SCI 논문 발표편수	책임	179편	173편	163편	184편	135편
공동	147편	120편	115편	136편	168편
합계	326편	293편	278편	320편	303편

2897. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

C E Geyer Jr 1, J E Garber 2, R D Gelber 3, G Yothers 4, M Taboada 5, L Ross 6, P Rastogi 1, K Cui 7, A Arahmani 8, G Aktan 9, A C Armstrong 10, M Arnedos 11, J Balmaña 12, J Bergh 13, J Bliss 14, S Delaloge 15, S M Domchek 16, A Eisen 17, F Elsafy 5, L E Fein 18, A Fielding 7, J M Ford 19, S Friedman 20, K A Gelmon 21, L Gianni 22, M Gnant 23, S J Hollingsworth 24, S-A Im 25, A Jager 26, Ó Þ Jóhannsson 27, S R Lakhani 28, W Janni 29, B Linderholm 30, T-W Liu 31, N Loman 32, L Korde 33, S Loibl

Ann Oncol. 2022 Dec;33(12):1250-1268. Link

2896. Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial

Hope S Rugo 1, Seock-Ah Im 2, Fatima Cardoso 3, Javier Cortes 4 5, Giuseppe Curigliano 6, Antonino Musolino 7 8 9, Mark D Pegram 10, Thomas Bachelot 11, Gail S Wright 12, Cristina Saura 13, Santiago Escrivá-de-Romaní 13, Michelino De Laurentiis 14, Gary N Schwartz 15, Timothy J Pluard 16, Francesco Ricci 17, William R Gwin 3rd 18, Christelle Levy 19, Ursa Brown-Glaberman 20, Jean-Marc Ferrero 21, Maaike de Boer 22, Sung-Bae Kim 23, Katarína Petráková 24, Denise A Yardley 25, Orit Freedman 26, Er

J Clin Oncol. 2023 Jan 10;41(2):198-205. doi: 10.1200/JCO.21.02937. Epub 2022 Nov 4. Link

2895. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

Javier Cortes 1, Hope S Rugo 1, David W Cescon 1, Seock-Ah Im 1, Mastura M Yusof 1, Carlos Gallardo 1, Oleg Lipatov 1, Carlos H Barrios 1, Jose Perez-Garcia 1, Hiroji Iwata 1, Norikazu Masuda 1, Marco Torregroza Otero 1, Erhan Gokmen 1, Sherene Loi 1, Zifang Guo 1, Xuan Zhou 1, Vassiliki Karantza 1, Wilbur Pan 1, Peter Schmid 1; KEYNOTE-355 Investigators

N Engl J Med. 2022 Jul 21;387(3):217-226. Link

2894. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

Shanu Modi 1, William Jacot 1, Toshinari Yamashita 1, Joohyuk Sohn 1, Maria Vidal 1, Eriko Tokunaga 1, Junji Tsurutani 1, Naoto T Ueno 1, Aleix Prat 1, Yee Soo Chae 1, Keun Seok Lee 1, Naoki Niikura 1, Yeon Hee Park 1, Binghe Xu 1, Xiaojia Wang 1, Miguel Gil-Gil 1, Wei Li 1, Jean-Yves Pierga 1, Seock-Ah Im 1, Halle C F Moore 1, Hope S Rugo 1, Rinat Yerushalmi 1, Flora Zagouri 1, Andrea Gombos 1, Sung-Bae Kim 1, Qiang Liu 1, Ting Luo 1, Cristina Saura 1, Peter Schmid 1, Tao Sun 1, Dhiraj Gambhire

N Engl J Med. 2022 Jul 7;387(1):9-20. Link

2893. Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study

Massimo Cristofanilli 1, Hope S Rugo 2, Seock-Ah Im 3, Dennis J Slamon 4, Nadia Harbeck 5, Igor Bondarenko 6, Norikazu Masuda 7, Marco Colleoni 8, Angela DeMichele 9, Sherene Loi 10, Hiroji Iwata 11, Ben O'Leary 12, Fabrice André 13, Sibylle Loibl 14, Eustratios Bananis 15, Yuan Liu 16, Xin Huang 16, Sindy Kim 16, Maria Jose Lechuga Frean 16, Nicholas C Turner 12

Clin Cancer Res. 2022 Aug 15;28(16):3433-3442 Link

2892. Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2- Advanced Breast Cancer in the MONALEESA-3 Trial

Guy Jerusalem 1, Thomas E Delea 2, Migule Martin 3, Michelino De Laurentiis 4, Arnd Nusch 5, J Thaddeus Beck 6, Arlene Chan 7, Seock-Ah Im 8, Patrick Neven 9, Alexander Lonshteyn 2, David Chandiwana 10, Brad Lanoue 10, Peter A Fasching 11

Clin Breast Cancer. 2022 Jun;22(4):326-335. Link

2891. The longitudinal effects of chronotype on chemotherapy-induced nausea and vomiting in patients with breast cancer receiving neoadjuvant chemotherapy

Sanghyup Jung 1, Kyung-Lak Son 2, Saim Jung 1, Jung Yoon Moon 1, Gyu Han Oh 3, Chan-Woo Yeom 4, Kwang-Min Lee 5, Won-Hyoung Kim 6, Dooyoung Jung 7, Tae-Yong Kim 8, Seock-Ah Im 9, Kyung-Hun Lee 8, David Spiegel 10, Bong-Jin Hahm 11

J Psychosom Res. 2022 Jun;157:110804. Link

2890. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

Javier Cortés 1, Sung-Bae Kim 1, Wei-Pang Chung 1, Seock-Ah Im 1, Yeon Hee Park 1, Roberto Hegg 1, Min Hwan Kim 1, Ling-Ming Tseng 1, Vanessa Petry 1, Chi-Feng Chung 1, Hiroji Iwata 1, Erika Hamilton 1, Giuseppe Curigliano 1, Binghe Xu 1, Chiun-Sheng Huang 1, Jee Hyun Kim 1, Joanne W Y Chiu 1, Jose Luiz Pedrini 1, Caleb Lee 1, Yali Liu 1, Jillian Cathcart 1, Emarjola Bako 1, Sunil Verma 1, Sara A Hurvitz 1; DESTINY-Breast03 Trial Investigators

N Engl J Med. 2022 Mar 24;386(12):1143-1154. Link

2889. Morning Chronotype Decreases the Risk of Chemotherapy-Induced Peripheral Neuropathy in Women With Breast Cancer

Kyung-Lak Son 1, Dooyoung Jung 2, Kwang-Min Lee 3, Chan-Woo Yeom 4, Gyu Han Oh 5, Tae-Yong Kim 6 7, Seock-Ah Im 6 7 8, Kyung-Hun Lee 6 7, David Spiegel 9, Bong-Jin Hahm 10

J Korean Med Sci. 2022 Feb 7;37(5):e34. Link

2888. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

Peter Schmid 1, Javier Cortes 1, Rebecca Dent 1, Lajos Pusztai 1, Heather McArthur 1, Sherko Kümmel 1, Jonas Bergh 1, Carsten Denkert 1, Yeon Hee Park 1, Rina Hui 1, Nadia Harbeck 1, Masato Takahashi 1, Michael Untch 1, Peter A Fasching 1, Fatima Cardoso 1, Jay Andersen 1, Debra Patt 1, Michael Danso 1, Marta Ferreira 1, Marie-Ange Mouret-Reynier 1, Seock-Ah Im 1, Jin-Hee Ahn 1, Maria Gion 1, Sally Baron-Hay 1, Jean-François Boileau 1, Yu Ding 1, Konstantinos Tryfonidis 1, Gursel Aktan 1, Vassil

N Engl J Med. 2022 Feb 10;386(6):556-567. Link

최근 5년 연구업적 현황